Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.63 SEK | -34.27% | -36.33% | -59.20% |
Sales 2024 * | - | Sales 2025 * | 98M 14M 153M | Capitalization | 64.67M 9.24M 101M |
---|---|---|---|---|---|
Net income 2024 * | -20M -2.86M -31.23M | Net income 2025 * | 72M 10.28M 112M | EV / Sales 2024 * | - |
Net cash position 2024 * | 67M 9.57M 105M | Net cash position 2025 * | 140M 20M 219M | EV / Sales 2025 * | -0.77 x |
P/E ratio 2024 * |
-16.5
x | P/E ratio 2025 * |
3.31
x | Employees | 4 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.68% |
Latest transcript on Scandion Oncology A/S
1 day | -43.15% | ||
1 week | -44.92% | ||
Current month | -43.82% | ||
1 month | -27.84% | ||
3 months | -69.94% | ||
6 months | +2.17% | ||
Current year | -64.71% |
Managers | Title | Age | Since |
---|---|---|---|
Jan Stenvang
FOU | Founder | - | 16-12-31 |
Chief Executive Officer | 64 | 23-01-01 | |
Johnny Stilou
DFI | Director of Finance/CFO | 57 | 21-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 62 | 22-03-31 | |
Director/Board Member | 69 | 18-05-06 | |
Martin Møller
CHM | Chairman | 49 | 21-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 1.63 | -34.27% | 1 522 555 |
24-04-18 | 2.48 | +2.48% | 8,478 |
24-04-17 | 2.42 | -3.20% | 16,933 |
24-04-16 | 2.5 | +0.40% | 29,358 |
24-04-15 | 2.49 | -2.73% | 40,026 |
Delayed Quote Nasdaq Stockholm, April 19, 2024 at 06:44 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-64.71% | 9.24M | |
-3.30% | 102B | |
+1.79% | 96.07B | |
-1.08% | 21.66B | |
-18.35% | 20.77B | |
-8.12% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B |
- Stock Market
- Equities
- SCOL Stock